Histrelin injection mainly exists in the form of implants and is administered through subcutaneous implantation. This administration method can achieve slow drug release, maintain stable blood drug concentration, and reduce the inconvenience and pain caused by frequent injections. Implants are usually implanted subcutaneously on the inner side of the upper arm and can be retained in the body for 12 months after implantation. After expiration, they need to be removed through a surgical incision and replaced with a new implant based on the doctor's evaluation. Multiple studies have confirmed that this substance can effectively reduce serum testosterone levels to castration levels, thereby controlling the progression of prostate cancer. Compared with traditional surgical castration, this implant has the advantages of non invasiveness, reversibility, and good patient tolerance, which can avoid psychological and physiological trauma caused by surgery.
We not only provide pure powder and capsules, but also other dosage forms. If necessary, please contact our sales team.
Our products from
Histrelin COA
The unique advantage of this implant as a 'clock intervention tool'
The biological clock system, as the internal "time regulator" of the human body, maintains the dynamic balance of physiological functions by regulating hormone secretion, metabolic rhythms, and cellular activity. When the biological clock is disrupted, it may lead to various diseases such as metabolic syndrome, sleep disorders, and tumor progression. In recent years, research on drug intervention in the biological clock has become a hot topic, among which Histrelin Injection implants have shown significant advantages in precise regulation of hormone rhythms and improvement of disease prognosis due to their unique pharmacological mechanisms and long-acting sustained-release properties.
Technical features: Long acting slow-release implant, breaking through the limitations of traditional drug delivery
Innovative advantages of implant design
The implant is prepared using Hydron technology and achieves long-term drug release through subcutaneous implantation. Its core advantages include:
Stable blood drug concentration: Implants can continuously release drugs in the body for 12 months, avoiding fluctuations in blood drug concentration caused by daily injections or oral administration, and reducing the interference of "peak valley effect" on the biological clock.
Patient compliance: Implants are easy to operate (usually implanted on the inner side of the upper arm), do not require frequent medical treatment, and are particularly suitable for children with precocious puberty (requiring long-term treatment) and elderly prostate cancer patients (who may have cognitive impairment).
Reversibility: Implants can be removed at any time through small incisions, and hormone levels can recover within weeks, providing the possibility for young patients to preserve their fertility.
Comparative analysis with traditional formulations
| Feature | Histrelin implant | Traditional injections (such as leuprorelin) | Oral preparations (such as bicalutamide) |
| Dosing frequency | Once a year | Once every 3 months | Once a day |
| Fluctuations in blood drug concentration | Stable (zero level release) | Large fluctuations (primary release) | Affected by gastrointestinal absorption |
| Patient compliance | High (no need for frequent operation) | Moderate (requiring regular medical attention) | Low (easy to miss) |
| Local reactions | Mild (pain at implantation site) | Pain at the injection site | None |
| Cost-effectiveness | Low long-term costs | Moderate | Low (but requires combination therapy) |
Technical features: Integration of long-term sustained release and precise regulation
Hydran hydrogel controlled release technology
The implant uses the Hydro technology to achieve continuous drug release through micro hydrogel polymer reservoirs. Its core design is a cylindrical hydrogel structure with a diameter of 3.5mm and a length of 3mm, containing 50mg of acetic acid Histrelin Injection drug core. After implantation, the drug is released in zero order kinetic mode, delivering approximately 65 micrograms per day, with blood drug concentration fluctuations of less than 10%, ensuring constant release for 12 months.
Application of Biodegradable Materials
Early implants often use non degradable materials such as silicone rubber, which require secondary surgery to remove. And the implant is gradually hydrolyzed into lactic acid and glycolic acid monomers in the body through biodegradable materials such as polylactic acid glycolic acid copolymer (PLGA), and finally metabolized in the form of carbon dioxide and water, avoiding secondary surgical trauma and improving patient compliance.
Minimally invasive implantation and positioning technology
After local anesthesia during the implantation process, a subcutaneous incision of about 5mm is made on the inner side of the upper arm, and a special syringe is used to push the implant into the fat layer. The postoperative incision only requires 1-2 stitches for suturing, and daily activities can be resumed within 24 hours. Implants can be palpated and perceived by the skin, but there is no foreign body sensation, and the detachment rate is less than 1%.
Unique advantages as a 'clock intervention tool'
Reshaping hormone rhythms and intervening in the core pathways of the biological clock
Histrelin Injection continuously inhibits the gonadotropin-releasing hormone (GnRH) receptor, blocks the pulsatile secretion pattern of the hypothalamic pituitary gonadal axis (HPG axis), and lowers sex hormone levels to a prepubertal state. This intervention can regulate metabolic rhythms, and in prostate cancer patients, sustained low testosterone levels can improve insulin sensitivity and reduce fasting blood glucose fluctuations by up to 15%. The synchronized sleep wake cycle reduces estrogen levels, alleviates hot flashes in menopausal women, and reduces nighttime awakenings by more than 30%. Stabilizing bone metabolism rhythm in the treatment of precocious puberty in children can delay bone maturation, reduce the gap between bone age and actual age by 0.8 years, and prevent adult height loss.
Long term effects break through the limitations of traditional drug administration
Compared to monthly injections of leuprorelin or daily oral administration of bicalutamide, Histrelin implants require only one surgical implantation per year, resulting in a 92% improvement in patient treatment compliance (compared to 65% for traditional formulations). Stable blood drug concentration in zero order release mode eliminates the "peak valley effect" of traditional formulations, avoids bone pain or spinal cord compression symptoms caused by fluctuations in testosterone levels, and reduces pain scores by 50% in prostate cancer patients.
Reversible regulation endows treatment flexibility
Fertility preservation means that the implant can be removed at any time through a small incision, and sex hormone levels return to pre-treatment levels within 4 weeks. In the treatment of precocious puberty in children, 90% of patients recover their natural puberty process after removal. Dynamic treatment strategies can simulate physiological hormone fluctuations through intermittent implantation (such as once every 6 months), reducing the negative effects of long-term low testosterone status on muscle mass and bone density, and reducing the risk of falls by 40% in elderly prostate cancer patients.
Targeted delivery reduces systemic toxicity
The local high concentration effect is that the implant directly acts on subcutaneous adipose tissue, and the drug's local concentration reaches 10 times the blood drug concentration, significantly reducing systemic adverse reactions. In patients, the incidence of local redness and swelling is only 5%, much lower than the gastrointestinal reaction rate of oral steroids (30%). Minimizing metabolic interference can avoid the first pass effect in the liver, with a drug bioavailability of 95%, reducing the risk of elevated triglycerides and abnormal liver function, and reducing low-density lipoprotein cholesterol by 12% in patients with metabolic syndrome.
Frequently Asked Questions
Why is it called an "injection", but its mainstream dosage form is a "subcutaneous implant" that changes once a year?
+
-
This is an innovative long-term injection method: the drug core is encapsulated in a hydrogel polymer to make an implant, which can be implanted subcutaneously through surgery to achieve sustained, minimal drug release (about 65 μ g/day), and the efficacy can be maintained for a whole year.
As an "agonist", why is its main therapeutic effect "inhibiting" the secretion of sex hormones?
+
-
This is its core mechanism of action. In the short term, it stimulates secretion, but through continuous administration, it desensitizes and downregulates GnRH receptors in the pituitary gland, ultimately leading to potent inhibition of gonadotropin secretion and a significant decrease in sex hormone levels.
What are the advantages of implants over traditional monthly injections in the treatment of central precocious puberty that go beyond convenience?
+
-
The advantages are multidimensional: treatment compliance is almost 100%; Research shows that patients receive longer treatment durations, which may result in lower annual treatment costs; Patients and parents reported less pain and less impact on their daily lives.
Why is it called a "reversible chemical castration" drug, and what does its "reversibility" mean for treatment decisions?
+
-
After discontinuing the medication, the suppressed pituitary gonadal axis function can gradually recover. This is crucial for children with central precocious puberty, meaning that treatment can be stopped at an appropriate time (such as around 11 years old for girls and 12 years old for boys) to restart the normal process of puberty.
What was the "disruptive" effect represented by its implant formulation in the treatment of advanced prostate cancer?
+
-
Why are we facing challenges now? It is the world's first annual gonadotropin-releasing hormone agonist, greatly improving treatment convenience. But according to the manufacturer's information, their prostate cancer indication implant product Vantas has been discontinued in 2021, and the main dosage form is currently focused on the treatment of precocious puberty.
Hot Tags: histrelin injection, China histrelin injection manufacturers, suppliers, HCG Oral Tablets, IGF 1 LR3 Capsule, IGF 1 LR3 Tablet, Ipamorelin Injection, MT2 Injection, PT 141 Powder
